AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29443750 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 29443750 — intervention group
Group type: EXPERIMENTAL
Intervention: roflumilast
Number of subjects: 120
Study 26640805 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII + Lira
Number of subjects: 39
Study 26640805 — intervention group
Group type: COMPARATOR
Intervention: CSII alone
Number of subjects: 39
Study 24096366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 149
Study 24096366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 149
Study 24096366 — intervention group
Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 149
Study 24096366 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 149
Study 22154766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, 2,000 mg/daily
Number of subjects: 132
Study 22154766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 21055319 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 160
Study 21055319 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 160
Study 21055319 — intervention group
Group type: COMPARATOR
Intervention: SCIT
Number of subjects: 160
Study 21055319 — intervention group
Group type: COMPARATOR
Intervention: SLIT
Number of subjects: 160
Study 17350152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum with lactoperoxidase (LP)
Number of subjects: 12
Study 17350152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum with micro granules of silicon dioxide (SD)
Number of subjects: 12
Study 17350152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum with zinc gluconate (ZG)
Number of subjects: 12
Study 17350152 — intervention group
Group type: COMPARATOR
Intervention: Additive-free (AF) gum
Number of subjects: 12
Study 14560075 — intervention group
Group type: EXPERIMENTAL
Intervention: Light mobilization program (intervention group)
Number of subjects: 457
Study 14560075 — intervention group
Group type: COMPARATOR
Intervention: Control group (primary health care treatment)
Number of subjects: 457
Study 14560075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 457
Study 14560075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 457
Study 14560075 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic returns of the intervention
Number of subjects: 457
Study 10693636 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-treated donor spleen cells
Number of subjects: 40
Study 10693636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9112348 — intervention group
Group type: EXPERIMENTAL
Intervention: Three pretransplant transfusions
Number of subjects: 423
Study 9112348 — intervention group
Group type: COMPARATOR
Intervention: No transfusions (control group)
Number of subjects: 423
Study 8227758 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ low (15‐25 mumol/l)
Number of subjects: 84
Study 8227758 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ high (28‐40 mumol/l)
Number of subjects: 84
Study 8227758 — intervention group
Group type: EXPERIMENTAL
Intervention: LI (0.6‐0.8 mumol/l)
Number of subjects: 84
Study 3512121 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Kampo education introduction into clinical training
Number of subjects: 888
Study 28253878 — intervention group
Group type: COMPARATOR
Intervention: Kampo education availability
Number of subjects: 888
Study 28253878 — intervention group
Group type: COMPARATOR
Intervention: Kampo education methods
Number of subjects: 888
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents' interest in Kampo medicine
Number of subjects: 888
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived value of learning Kampo medicine
Number of subjects: 888
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with training
Number of subjects: 888
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to learn Kampo medicine
Number of subjects: 888
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of Western and Kampo medicine
Number of subjects: 888
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of Kampo medicine
Number of subjects: 888
Study 28253878 — intervention group
Group type: EXPERIMENTAL
Intervention: Reluctance to prescribe after residency
Number of subjects: 888
Study 26448147 — intervention group
Group type: EXPERIMENTAL
Intervention: IL–1 receptor antagonist IL‐1Ra (anakinra)
Number of subjects: 17
Study 26448147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23557450 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention at the time of diagnosis
Number of subjects: 0
Study 23557450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 0
Study 21168369 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A) adjuvanted vaccine (3.75 μg of haemagglutinin)
Number of subjects: 347
Study 21168369 — intervention group
Group type: COMPARATOR
Intervention: Whole-virion vaccine (7.5 μg of haemagglutinin)
Number of subjects: 347
Study 19298916 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) 0.042 microg/kg/min; ANP group, n = 126
Number of subjects: 254
Study 19298916 — intervention group
Group type: COMPARATOR
Intervention: Ringer solution alone; control group, n = 128
Number of subjects: 254
Study 19298916 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 254
Study 17551148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 22507
Study 17551148 — intervention group
Group type: COMPARATOR
Intervention: Nonaspirin NSAID use
Number of subjects: 22507
Study 15309603 — intervention group
Group type: EXPERIMENTAL
Intervention: Late summer months (August/September)
Number of subjects: 65
Study 15309603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid‐winter (January/February)
Number of subjects: 65
Study 15309603 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall UCa/Cr
Number of subjects: 65
Study 11573662 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA insertion (n=20)
Number of subjects: 40
Study 11573662 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopy and tracheal intubation (n=20)
Number of subjects: 40
Study 9183508 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge-drinking events
Number of subjects: 1914
Study 9183508 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of the number of drinks required to impair driving
Number of subjects: 1914
Study 9183508 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking location (outdoors or in a moving car/truck)
Number of subjects: 1914
Study 9183508 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking occasions (specific to females)
Number of subjects: 1914
Study 9183508 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking at someone else's house (specific to females)
Number of subjects: 1914
Study 8188554 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 2
Study 8188554 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 2
Study 8188554 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg
Number of subjects: 2
Study 8188554 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up dose based on trial-phase data
Number of subjects: 2
Study 8188554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 3499456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg body weight)
Number of subjects: 14
Study 3499456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 14
Study 3499456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31978372 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 161
Study 31978372 — intervention group
Group type: COMPARATOR
Intervention: Conventional obesity treatment
Number of subjects: 161
Study 30177465 — intervention group
Group type: EXPERIMENTAL
Intervention: FMOS lipid emulsion
Number of subjects: 67
Study 30177465 — intervention group
Group type: COMPARATOR
Intervention: OO/SO lipid emulsion
Number of subjects: 67
Study 28916667 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMT (mechanical thrombectomy combined with intravenous thrombolysis)
Number of subjects: 402
Study 28916667 — intervention group
Group type: COMPARATOR
Intervention: IVT (intravenous thrombolysis)
Number of subjects: 402
Study 25635361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without syndesmotic injury
Number of subjects: 242
Study 25635361 — intervention group
Group type: COMPARATOR
Intervention: Patients with syndesmotic injury
Number of subjects: 242
Study 23930638 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 62
Study 23930638 — intervention group
Group type: COMPARATOR
Intervention: Monitoring without further treatment (Control)
Number of subjects: 62
Study 22973331 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 72
Study 22973331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20201159 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic physiotherapy (customised programme including postisometric relaxation, active mobilisation, Kibler Fold mobilisation, Kinesiology Taping, Maigne's relaxing exercises)
Number of subjects: 60
Study 20201159 — intervention group
Group type: COMPARATOR
Intervention: Electrotherapy and standard exercises for low back pain
Number of subjects: 60
Study 17466494 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial magnetic stimulation (TMS)
Number of subjects: 99
Study 17466494 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 99
Study 15180756 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks for 12 months)
Number of subjects: 312
Study 15180756 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 312
Study 15180756 — intervention group
Group type: COMPARATOR
Intervention: Best Standard Care (BSC) alone
Number of subjects: 312
Study 11871867 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment options for pruritus in cancer patients; specific interventions not detailed.
Number of subjects: 0
Study 9619655 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterlow scores (all subjects)
Number of subjects: 9172
Study 9619655 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden scores (wheelchair users)
Number of subjects: 9172
Study 9619655 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterlow scores (wheelchair users)
Number of subjects: 9172
Study 8302503 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly one hour exercise classes supervised by a physiotherapist
Number of subjects: 34
Study 8302503 — intervention group
Group type: COMPARATOR
Intervention: Regular rest home activities without physiotherapy input
Number of subjects: 34
Study 2720716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 13
Study 30113209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sensorimotor intervention (15-minute program: stroking peri‐oral structures for 5 minutes, tongue exercises for 5 minutes, non‐nutritive sucking for 5 minutes, administered once daily for 10 days)
Number of subjects: 31
Study 30113209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sensorimotor intervention
Number of subjects: 31
Study 30113209 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham intervention for the same duration)
Number of subjects: 31
Study 28043015 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfolding nursing cases
Number of subjects: 122
Study 28043015 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing cases
Number of subjects: 122
Study 25925026 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.241%
Number of subjects: 0
Study 23953766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesicoamniotic shunt
Number of subjects: 31
Study 23953766 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 31
Study 23953766 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study 21600388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B(12) 1000 μg daily for 90 days
Number of subjects: 50
Study 21600388 — intervention group
Group type: COMPARATOR
Intervention: IM B(12) 1000 μg in 9 injections over 3 months
Number of subjects: 50
Study 19457640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FS) 120mg
Number of subjects: 13
Study 19457640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium iron ethylenediaminetetra-acetic acid (EDTA) 5mg
Number of subjects: 13
Study 19457640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated cell fraction (DCF) high-dose 120mg
Number of subjects: 13
Study 19457640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated cell fraction (DCF) low-dose 5mg
Number of subjects: 13
Study 16698309 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1 (OPTI-FREE RepleniSH MPDS, Alcon Laboratories Inc.)
Number of subjects: 362
Study 15180835 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect diode laser photocoagulation
Number of subjects: 36
Study 15180835 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 36
Study 11207509 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg on-demand therapy
Number of subjects: 342
Study 11207509 — intervention group
Group type: COMPARATOR
Intervention: Placebo on-demand therapy
Number of subjects: 342
Study 11207509 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg and Placebo
Number of subjects: 342
Study 9421340 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course for index group (n = 12 doctors)
Number of subjects: 28
Study 9421340 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (n = 12 doctors)
Number of subjects: 28
Study 9421340 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (n = 4 doctors)
Number of subjects: 28
Study 2019804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate swabs
Number of subjects: 99
Study 2019804 — intervention group
Group type: COMPARATOR
Intervention: Gauze swabs
Number of subjects: 99
Study 7047575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day)
Number of subjects: 51
Study 30266677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine (ID-AraC) plus G-CSF
Number of subjects: 90
Study 30266677 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 90
Study 26738812 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03049423 6 mg
Number of subjects: 70
Study 26738812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23340738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 100 mg/m² on days 1 and 2 of a 4-week cycle
Number of subjects: 92
Study 23340738 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine 25 mg/m² on days 1 to 5 every 4 weeks
Number of subjects: 92
Study 21320116 — intervention group
Group type: EXPERIMENTAL
Intervention: Single seizure only
Number of subjects: 253
Study 21320116 — intervention group
Group type: EXPERIMENTAL
Intervention: Early remission
Number of subjects: 253
Study 21320116 — intervention group
Group type: EXPERIMENTAL
Intervention: Late remission
Number of subjects: 253
Study 21320116 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse after seizure-free period
Number of subjects: 253
Study 21320116 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent seizures
Number of subjects: 253
Study 19229667 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenously weekly)
Number of subjects: 100
Study 19229667 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (3 million units subcutaneously three times weekly, escalating to 18 MU)
Number of subjects: 100
Study 19229667 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 100
Study 19229667 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 100
Study 19229667 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus vs Interferon-alpha
Number of subjects: 100
Study 16735934 — intervention group
Group type: EXPERIMENTAL
Intervention: lasofoxifene 0.25 mg/day
Number of subjects: 410
Study 16735934 — intervention group
Group type: EXPERIMENTAL
Intervention: lasofoxifene 1.0 mg/day
Number of subjects: 410
Study 16735934 — intervention group
Group type: COMPARATOR
Intervention: raloxifene 60 mg/day
Number of subjects: 410
Study 16735934 — intervention group
Group type: COMPARATOR
Intervention: lasofoxifene and raloxifene
Number of subjects: 410
Study 15509758 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the somatosensory cortex contralateral to the hand
Number of subjects: 0
Study 15509758 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 11221551 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9846844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (30 mg)
Number of subjects: 11
Study 9846844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7919465 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFN beta (Frone) administered by intramuscular injection at a dosage of 5 Million Units (MU)/m2 three times weekly for six months
Number of subjects: 65
Study 7919465 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFN beta (Frone) administered by intramuscular injection
Number of subjects: 65
Study 7919465 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 65
Study 3041817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone plus piperacillin
Number of subjects: 30
Study 3041817 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin plus tobramycin
Number of subjects: 30
Study 29463211 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every 2 hours
Number of subjects: 951
Study 29463211 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every 3 hours
Number of subjects: 951
Study 29463211 — intervention group
Group type: EXPERIMENTAL
Intervention: Repositioning every 4 hours
Number of subjects: 951
Study 26869500 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional mail (pen and paper)
Number of subjects: 73
Study 26869500 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 73
Study 26869500 — intervention group
Group type: COMPARATOR
Intervention: E-mail
Number of subjects: 73
Study 26869500 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional mail and telephone
Number of subjects: 73
Study 25783647 — intervention group
Group type: EXPERIMENTAL
Intervention: SWETZ
Number of subjects: 164
Study 25783647 — intervention group
Group type: COMPARATOR
Intervention: LLETZ-cone
Number of subjects: 164
Study 25783647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 164
Study 23027701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mehran risk score - high risk (11-15)
Number of subjects: 1041
Study 23027701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mehran risk score - very high risk (≥16)
Number of subjects: 1041
Study 23027701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mehran risk score - moderate risk (6-10)
Number of subjects: 1041
Study 23027701 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-induced nephropathy (CIN)
Number of subjects: 1041
Study 21345600 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6% garlic treatment group
Number of subjects: 31
Study 21345600 — intervention group
Group type: COMPARATOR
Intervention: 0% garlic treatment group
Number of subjects: 31
Study 21345600 — intervention group
Group type: COMPARATOR
Intervention: 1.8% garlic treatment group
Number of subjects: 31
Study 17617188 — intervention group
Group type: EXPERIMENTAL
Intervention: NovaSure (bipolar radio-frequency ablation)
Number of subjects: 126
Study 17617188 — intervention group
Group type: COMPARATOR
Intervention: ThermaChoice (balloon ablation)
Number of subjects: 126
Study 16339606 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution (2.5 mg/kg twice daily)
Number of subjects: 494
Study 16339606 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole oral solution or capsules (400 mg daily)
Number of subjects: 494
Study 12580982 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir/ritonavir 2,000/200 mg with a full breakfast
Number of subjects: 27
Study 12580982 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir/ritonavir 2,000/400 mg with a full breakfast
Number of subjects: 27
Study 12580982 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir/ritonavir 2,500/200 mg with a full breakfast
Number of subjects: 27
Study 12580982 — intervention group
Group type: COMPARATOR
Intervention: nelfinavir/ritonavir with a light breakfast
Number of subjects: 27
Study 10951826 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (initial dose 12.5 mg, increased weekly to 75 mg/day)
Number of subjects: 30
Study 10951826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8733066 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 7908570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate 12.5 mg/kg intravenously within an hour of delivery, followed by doses at six-hourly intervals for four days (total dose 200 mg/kg)
Number of subjects: 171
Study 7908570 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.1 mL/kg intravenously
Number of subjects: 171
Study 7908570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate 12.5 mg/kg intravenously
Number of subjects: 171